# VRNO earnings call intelligence LOPJLB CallCard / temporal rollup · freemium · [stock page](https://www.lopjlb.com/stock/VRNO) · [Earnings tab](https://www.lopjlb.com/stock/VRNO?tab=earnings) Updated: 2026-10-29T06:04:51 Quarters analyzed: 8 ## Cross-quarter narrative Verano’s earnings narrative shifts from early‑year revenue records and margin expansion to a later focus on pricing headwinds, regulatory ambiguity, and selective growth. Q2‑Q3 2023 highlighted record revenue, pricing stabilization and aggressive expansion into new adult‑use markets (Maryland, New Jersey, Connecticut). By Q4 2023 the company flagged retail price compression in New Jersey and Illinois and began betting on automation to protect EBITDA margins near 31%. The 2024 Q1‑Q2 calls emphasized strong wholesale demand, Florida indoor cultivation build‑out, and continued debt‑prepayment, while retail softness in New Jersey persisted. Mid‑2024 introduced wholesale credit holds and supply constraints in Florida, prompting a strategic pull‑back of wholesale volume. The 2024 Q4 and 2025 Q2 calls show a pivot to cost discipline, modest retail growth, higher gross margins, and a trimmed CapEx plan, yet regulatory uncertainty around DEA rescheduling and state adult‑use approvals remains a dominant risk. Across the period, milestone delivery has been mixed—several expansion projects have launched, while legislative and licensing risks linger, and pricing pressure has become a recurring theme. ## Latest CallCard · Q2 Verano reports modest retail growth, higher margins from efficiency gains, a strategic wholesale pull‑back and ongoing litigation, while targeting a stronger back half with continued product innovation. **Guidance:** maintained — Management expects to keep a ~30% adjusted EBITDA margin and modest wholesale improvement in the back half of 2025. **Tone:** mgmt 0.6 · Q&A pressure 0.4 · divergence 0.2 Prepared remarks highlighted progress on efficiencies, product innovation and confidence in maintaining a 30% adjusted EBITDA margin in the back half. ### Demand visibility Retail up modestly, wholesale down amid competition and AR strategy. Retail revenue rose 3% YoY driven by Ohio, Virginia, Arizona and Florida; wholesale revenue fell 8% sequentially due to price compression, new dispensaries and a pause in Massachusetts, while the accounts‑receivable strategy limits short‑term sales. ### Margins / costs Gross margin improved to highest in years on efficiency and mix benefits. Margin boost driven by cultivation/production efficiencies, higher vertical mix, lower third‑party wholesale mix, and cost improvements in Florida and Illinois operations. ### Capital allocation CapEx $10M Q2; full‑year $30‑45M; debt refinancing underway; cash $69M. Quarterly CapEx focused on operational efficiencies and retail expansion; $12M early repayment of Cannabist note, $29M income taxes paid, and proactive refinancing discussions ahead of the Oct 2026 term‑loan maturity. ### Milestones - **2 new Zen Leaf dispensaries in Connecticut** [delivered]: Opened two new Zen Leaf stores in Connecticut during Q2. - **Curbside pickup at sixth Ohio Zen Leaf location** [delivered]: Launched curbside pickup at the Antwerp, Ohio Zen Leaf store. - **New MÜV location in Florida** [delivered]: Added one new MÜV dispensary in Florida. - **Exclusive partnership with Grow Sciences in Illinois** [new]: Ink partnership to bring award‑winning products to the Illinois market. - **Line extensions and vape market‑share increase** [on_track]: Extended portfolio lines, achieving a 44% increase in vape market share across BDSA‑tracked markets. ### Fears / risks - **Competition**: Dozens of new third‑party dispensaries in Illinois and New Jersey intensify pricing pressure. - **Regulatory**: Uncertainty around cannabis rescheduling and adult‑use legislation in Virginia, Pennsylvania and Florida. - **Liquidity**: Need to refinance term loan before its October 2026 maturity. - **Litigation**: Ongoing lawsuit against Vireo seeking $15 million termination fee plus additional damages. - **Market demand**: Wholesale demand weakened as the accounts‑receivable strategy suppresses short‑term sales. - **Supply chain**: Inventory adjustments required due to lower sell‑through and price compression. ### Key quotes > “We advanced key priorities focused on delivering efficiencies, product innovation, automation and differentiation, which will continue throughout the course of the year.” > “We expect to maintain our historical 30% adjusted EBITDA margin profile throughout the back half of the year.” > “Our approach here has been a sales, not a sale until we actually collect the dollars. So you won't see a drastic ramp-up in wholesale.” ## Quarter one-liners - **2025 Q2:** Verano reports modest retail growth, higher margins from efficiency gains, a strategic wholesale pull‑back and ongoing litigation, while targeting a stronger back half with continued product innovation. - **2024 Q4:** Verano Q4 revenue $218M, adj EBITDA $63M; full year $879M revenue, $264M adj EBITDA; wholesale strength, new product launches, CapEx cut to $25-40M, M&A optionality, Florida momentum, Virginia growth, 280E tax adjustments. - **2024 Q3:** Verano Q3 revenue fell to $217M on Florida supply constraints, IL/NJ competition, and wholesale credit cuts; management emphasizes cost discipline, rescheduling optimism, and minimal 2025 CapEx after Florida expansion. - **2024 Q2:** Verano Q2 revenue $222M, adj - **2024 Q1:** Verano posted Q1 revenue of $221M, 30% adjusted EBITDA margin, highlighted strong wholesale growth, Florida adult‑use expansion and cautious optimism on DEA rescheduling while noting retail softness in New Jersey. - **2023 Q4:** Verano posted record revenue and cash flow, expanded dispensaries and product lines, but flagged retail sales pressure in New Jersey and pricing challenges while betting on automation, adult‑use rollouts and possible DEA rescheduling. - **2023 Q3:** Verano posted Q3 2023 revenue of $240 M (+5% YoY), raised full‑year free cash flow guidance, highlighted strong demand and new CBOE Canada listing while noting legislative and pricing uncertainties. - **2023 Q2:** Verano posted record Q2 revenue of $234M (+3% sequential), 31% adj. EBITDA margin, raised FCF guidance to $65-75M, cited pricing stabilization, inventory reductions, 280E decoupling in key states, and Maryland adult-use launch. ## Theme arcs - **Pricing pressure in NJ/IL** (deteriorating): Retail price compression noted repeatedly from Q3 2023 through Q2 2025 - **Regulatory uncertainty (DEA rescheduling)** (stable): Rescheduling optimism persists but outcome remains unknown across all calls - **Wholesale demand and credit strategy** (new): Strong wholesale growth early, followed by credit‑hold strategy introduced Q3 2024 - **Adult‑use market rollout** (new): New launches in Maryland, Florida, Ohio, Virginia with mixed timing - **Margin stability** (improving): Adjusted EBITDA margin steadied around 30‑31% despite pricing headwinds - **Capital allocation and debt reduction** (improving): Consistent debt prepayments and reduced CapEx from $50M to $25‑40M - **Retail softness in NJ** (deteriorating): Repeated retail sales decline linked to rapid store openings - **Automation and efficiency initiatives** (new): Automation rollout on‑track from Q4 2023, linked to margin protection ## Guidance path 2023 Q2:raised → 2023 Q3:raised → 2023 Q4:maintained → 2024 Q1:maintained → 2024 Q2:vague → 2024 Q3:vague → 2024 Q4:vague → 2025 Q2:maintained --- Research context only. Not personalized investment advice. API: `GET /bff/api/bigfive/earnings-intel/VRNO`